Recon: CBER chief said FDA’s confidence in gene editing is growing; Belgium confiscates counterfeit weight-loss drugs

• After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy (STAT)
• US FDA’s Confidence In Gene Editing Safety Growing Enough That Regulatory Bar May Be Lowered (Pink Sheet)
• Moderna reins in 2023 COVID vaccine forecast, shares tumble (Reuters)
• Updated: Eli Lilly's Mounjaro sales hit $1.4B for the quarter, but FDA decision on Alzheimer's drug is delayed (Endpoints)
• Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month (Reuters)

• EMA To Address Scientific Advances In Guidance For Flu Vaccine Innovators (Pink Sheet)
• EU’s ‘Significant Benefit’ Metric For Orphan Drugs Still A Thorn In Industry’s Side (Pink Sheet)
• Belgium seizes fake weight-loss drugs containing insulin (Reuters)
• Shanghai Eyes Commercial Insurance Push To Address Drug Firms’ Pricing Concerns (Pink Sheet)

• BioMarin's longtime CEO Jean-Jacques Bienaimé hands the reins to Genentech's Alexander Hardy (Fierce Pharma)
• Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis (STAT)
• UPDATE 6-Novo Nordisk flags big 2024 sales boost despite Wegovy curbs (Reuters)
• Novo Nordisk: obesity drugs priority over century-old focus on insulin (Reuters)
• Novo Nordisk tempers expectations for hefty M&A deals as diabetes, obesity sales soar (Endpoints)
• CVS and Walgreens say pharmacist work action had minimal impact (Reuters)
• Nostrum Labs and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates (STAT)
• New antibiotic targets gonorrhea as well as last existing treatment, study shows (STAT)
• Sangamo sheds staff once again in another retreat (Pharmaphorum)
• Gene editing has had a big week in the spotlight. Here’s what’s going on (STAT)
• Gene therapy biotech Locanabio to shutter by year’s end (Endpoints)
• Intellia suggests ATTR amyloidosis gene editing treatment has over a year of durability as it gears up for PhIII (Endpoints)

• EU Regulatory Roundup, October 2023: Notified Bodies Fire On All Cylinders To Manage Challenges (MedTech Insight)
• Treating Rural America: The telehealth solution (STAT)
• With a new center, All of Us tackles health data silos to power precision medicine (STAT)
• CooperCompanies buys reproductive health products from Cook Medical after failed takeover (MedTech Dive)
• Drilling down on obesity drugs: What medtech executives are saying (MedTech Dive)
• FDA warning letter accuses Wavi of selling unapproved neurological device (MedTech Dive)
• Can Digital Twin Technology Help Beat Chronic Disease? Twin Health Is Getting Users Hooked, And Off Their Meds (MedTech Insight)
• SerenOx Africa Addresses Drug-Dx/Chicken-Egg Problem In African Health Care (MedTech Insight)
• Leo Grady’s Jona Hopes To Repair Microbiome Testing’s Murky Reputation (MedTech Insight)

• Do celebrity vaccine endorsements like Travis Kelce’s actually change behavior? (STAT)
• US hospital groups sue Biden administration to block ban on web trackers (Reuters)
• A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny? (FDA Law Blog)
• Stryker’s Lisa Kloes talks cementless implants, robotics as future of knee business (MedTech Dive)